Le Lézard
Classified in: Health
Subject: FDA

IntraFuse Receives FDA 510(k) Clearance for FlexThreadtm Fibula Pin System



LOGAN, Utah, Nov. 1, 2017 /PRNewswire/ -- IntraFuse, a start-up medical device company focused on advanced surgical devices for improving outcomes for orthopaedic extremity procedures, announces that it has received FDA 510(k) clearance for its FlexThreadtm Fibula Pin System.

The IntraFuse FlexThreadtm Fibula Pin System provides percutaneous fixation of distal fibula fractures, primarily Danis-Weber B type fractures, or trans-syndesmotic fractures.  The simple and elegant design is easy to insert and cost competitive with today's standard-of-care internal fixation hardware. Incorporating IntraFuse's proprietary FlexThreadtm technology, the distal end of the implant is a flexible, intramedullary screw and the proximal end is a rigid, high-strength intramedullary rod.  Upon insertion of the implant into the fibula, the rigid rod portion of the implant spans and supports the fracture and the flexible screw portion bends as needed to thread into the intramedullary canal.  With internal screw fixation on one side of the fracture and cross screw fixation through the rod on the other side of the fracture, proper bone alignment and length can be maintained during the healing period. Additionally, the FlexThreadtm Fibula Pin is compatible with either screw or flexible fixation of the syndesmosis joint as needed.

To accommodate the anatomic size range of fibulas, the FlexThreadtm Fibula Pin is available in three different screw diameters, each with two length options.  Using routine intramedullary and screw fixation techniques, bone preparation is a simple, three step sequence:  place guide wire, ream, tap.   Optional fracture site compression is achieved concurrent with insertion of the implant, and delivery of cross fixation screws is facilitated by a guide that connects directly to the implant inserter.    

The FlexThreadtm Fibula Pin provides anatomic, intramedullary fixation that may have potential clinical advantages over fibula plating systems, including: reduced risk of hardware related pain, reduced rate of hardware removal, less risk of wound complications, infection and other morbidities due to a less invasive procedure, and less disruption of the periosteum which facilitates faster healing.

"Intramedullary fixation is the standard-of-care today for most fractures of the large, long bones of the body due to superior clinical outcomes versus plating systems, yet plating systems are still the standard-of-care for the smaller, long bones of the extremities," states Wade Fallin, CEO of IntraFuse.  Fallin continues, "FlexThreadtm is a platform technology that can address the unique requirements for intramedullary fixation of small bone fractures where off-axis entry into the bone canal is required, or where the bone is curved.  Now cleared for both clavicle and fibula fractures, the FlexThreadtm technology is in further development for additional indications."

IntraFuse is a development stage medical device company incubated and operated by Surgical Frontiers.  Inquiries regarding distribution and commercialization partnerships are welcome.

About Surgical Frontiers

Surgical Frontiers funds, launches and operates start-up companies to develop advanced surgical technologies that are ready for clinical use.   Focused primarily on musculoskeletal injuries and pathologies, the company collaborates with surgeons, industry, universities, and investors to bring advanced surgical technologies to the market that improve healthcare.  

Contacts:

Mr. Wade Fallin
CEO 
182962@email4pr.com 
www.surgicalfrontiers.com   
800-230-3710

SOURCE IntraFuse


These press releases may also interest you

at 11:30
FUJIFILM Medical Systems U.S.A., Inc., a leading provider of diagnostic imaging and medical informatics solutions, today introduced the FCT Embrace. Powered by Analogic, the FCT Embrace is the world's first 85cm wide bore computed tomography (CT)...

at 10:00
During its Users Meeting at the 2018 American Society for Radiation Oncology (ASTRO) Annual Meeting, Varian shared details of its development work on an artificial intelligence (AI)-driven multimodality adaptive radiotherapy treatment suite that is...

at 09:30
Varian today announced the Bravostm afterloader system for High Dose Rate (HDR) brachytherapy treatments. Based on over five years of in-clinic research, Bravos is an integrated system designed to improve the patient and clinic experience by...

at 09:00
DxTerity, a molecular information and diagnostics company developing at-home RNA monitoring blood tests for immune-mediated diseases, today announced that data from systemic lupus erythematosus (SLE) and multiple sclerosis (MS) studies will be...

at 09:00
Royal Philips , a global leader in health technology, is showcasing its new suite of radiation oncology systems and software at the American Society for Radiation Oncology's (ASTRO) 60th Annual Meeting and Exhibition in San Antonio, Texas. Seamlessly...

at 08:59
BioArctic AB (publ) announced today that the European Patent Office (EPO) has issued a decision to grant the company's patent application in Europe, EP09738534.8, for its Parkinson's disease concept patent. The decision states that the European...




News published on 1 november 2017 at 08:45 and distributed by: